NCT06992258 2026-03-17
FRUITION
Criterium, Inc.
Phase 2 Recruiting
Clinical Trials
6 trialsNCT05343013 2026-03-06
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07361003 2026-01-22
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT07212933 2025-10-08
RAK in GC
Chinese PLA General Hospital
Phase 2 Recruiting
NCT07085169 2025-07-25
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
Ruijin Hospital
Phase 2 Recruiting
NCT04920032 2025-04-08
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
University of California, Irvine
Phase 1 Recruiting